Skip to main content
Premium Trial:

Request an Annual Quote

Epitomics to Develop Antibodies for Mass Spec Assays in Support of CPTC

Premium

Antibody maker Epitomics this week announced that it has signed a contract with SAIC-Frederick to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer program.

The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma. The antibodies will be used for immuno-enrichment of target peptides in mass spec workflows like stable isotope standards and capture by anti-peptide antibodies, or SISCAPA, and immuno-MALDI mass spec.

Epitomics has completed the first phase of the project, which called for it to generate and affinity-purify polyclonal antibodies against the biomarkers. In the current phase it will generate monoclonal antibodies against biomarkers validated during Phase 1.

CPTC is a five-year, $104 million effort to develop proteomics tools and technologies to accelerate discovery and clinical research. In July SAIC-Frederick signed a deal with Precision Antibodies to provide antibody and antigen characterization of antibodies used in the CPTC initiative, which followed on a contract Precision won from SAIC-Frederick in 2009 to develop monoclonal antibodies for the program (PM 07/30/2010).

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.